Darmstadt, Germany, June 8, 2016 – Merck, a leading science and technology company, today announced an increased commitment to its corporate venture fund under the new Merck Ventures roof. Four dedicated investment teams will focus on Healthcare, Life Science, Performance Materials and new businesses. The total volume of the newly set-up corporate venture fund of Merck is € 300 million, doubling the volume of the previous biopharma venture fund of € 150 million.
“Merck is a leading science and technology company, with three strong innovative business sectors. Beyond the innovation activities in our current businesses, we benefit significantly from the strategic investments we make through MS Ventures in our core fields and beyond our current scope. Roel [Bulthuis] has been instrumental in building the fund and is the driving force behind it.”